DreamCIS, Inc. (KOSDAQ:223250)

Market Cap	111.86B
Revenue (ttm)	63.74B
Net Income (ttm)	6.41B
Shares Out	23.80M
EPS (ttm)	267.12
PE Ratio	17.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,002
Average Volume	315,440
Open	4,700.00
Previous Close	4,700.00
Day's Range	4,450.00 - 4,700.00
52-Week Range	2,435.00 - 5,200.00
Beta	0.36
RSI	57.39
Earnings Date	Nov 14, 2025

About DreamCIS

DreamCIS, Inc. provides clinical research services in South Korea. It offers clinical development services; biostatic, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd.

• Industry: Commercial Physical and Biological Research
• Founded: 2000
• Employees: 354
• Stock Exchange: KOSDAQ
• Ticker Symbol: 223250

Financial Performance

In 2024, DreamCIS's revenue was 58.65 billion, an increase of 22.59% compared to the previous year's 47.84 billion. Earnings were 5.28 billion, an increase of 41.22%.